Mednet Logo
HomeRadiation OncologyQuestion

How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?

9
5 Answers
Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

The short answer is, YES I would, in general, recommend treatment.

I also respectfully disagree that ADT monotherapy is the standard of care. It is an option of course, but rarely performed given it is non-curative and the data to support its use is of minimal relevance today.

Some key points of reas...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

Some minor points that might add to the discussion.

Should adjuvant RT be given?

If the vast majority of men with pN+ disease have biochemical recurrence, then do the big randomized trials comparing adjuvant vs early salvage apply? Or should we just wait for PSA to recur and then treat?

While the ARTIS...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Michigan Healthcare Professionals, PC

The Messing trial established that these patients should be getting long term ADT (if not life-long), and though it was a small study, ADT dramatically improved survival.

So, the question really is, should you add RT? There is not prospective evidence, however there is a large series (Mayo + Milan) ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

These subsets were not included in all post op studies comparing early salvage vs adjuvant treatment. Published data suggest a high risk of BCR in this subset of node-positive post op patients without any adjuvant treatment. ADT alone is probably not curative. I favor adjuvant RT plus ADT unless pos...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Radiant Oncology

@Dr. First Last - What are your thoughts on the addition of Abiretarone to this patient population? The STAMPEDE trial was for intact prostate. Would insurance ever consider coverage for post-RP patients with N+ disease? Thank you!

Register or Sign In to see full answer